最近用于治疗 SARS-CoV-2 感染和 COVID-19 的药物开发和药物化学方法。
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19.
机构信息
Department of Chemistry, Purdue University, West Lafayette, IN, 47907, USA.
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA.
出版信息
ChemMedChem. 2022 Nov 18;17(22):e202200440. doi: 10.1002/cmdc.202200440. Epub 2022 Oct 13.
COVID-19, caused by SARS-CoV-2 infection, continues to be a major public health crisis around the globe. Development of vaccines and the first cluster of antiviral drugs has brought promise and hope for prevention and treatment of severe coronavirus disease. However, continued development of newer, safer, and more effective antiviral drugs are critically important to combat COVID-19 and counter the looming pathogenic variants. Studies of the coronavirus life cycle revealed several important biochemical targets for drug development. In the present review, we focus on recent drug design and medicinal chemistry efforts in small molecule drug discovery, including the development of nirmatrelvir that targets viral protein synthesis and remdesivir and molnupiravir that target viral RdRp. These are recent FDA approved drugs for the treatment of COVID-19.
由 SARS-CoV-2 感染引起的 COVID-19 仍然是全球范围内的主要公共卫生危机。疫苗的开发和第一批抗病毒药物的出现为严重冠状病毒病的预防和治疗带来了希望。然而，继续开发更新、更安全、更有效的抗病毒药物对于对抗 COVID-19 和应对潜在的致病性变体至关重要。对冠状病毒生命周期的研究揭示了几个重要的生化靶标，可用于药物开发。在本综述中，我们重点介绍了小分子药物发现中最近的药物设计和药物化学研究进展，包括靶向病毒蛋白合成的 nirmatrelvir 和靶向病毒 RdRp 的 remdesivir 和 molnupiravir 的开发。这些是最近获得 FDA 批准用于治疗 COVID-19 的药物。
Zotero 插件